Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to EGFR and HER3, inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody dependent cell mediated cytotoxicity. High tumor-expression of neuregulin 1 (NRG1), a ligand to HER3, m...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2016-10-01
coleção:	Frontiers in Oncology
Assuntos:	EGFR HPV cetuximab HER3 Nrg1 SCCHN
Acesso em linha:	http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00232/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!